@article{3192210,
    title = "Patient-reported outcomes (PROs) from IMvigor130: A global, randomised,
partially blinded phase III study of atezolizumab (atezo) plus
platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in
previously untreated locally advanced or metastatic urothelial carcinoma
(mUC)",
    author = "Bamias, A. and De Santis, M. and Arranz, J. A. and Grande, E. and and Galsky, M. D. and Kikuchi, E. and Park, S. H. and De Giorgi, U. and and Garcia del Muro, X. and Mencinger, M. and Alekseev, B. and Puente, J. and and Izumi, K. and Gumus, M. and Mellado Gonzalez, B. and Li, J-R. and and Quach, C. and Ding, B. and Bernhard, S. and Davis, I. D.",
    journal = "Annals of Oncology",
    year = "2020",
    volume = "31",
    number = "4",
    pages = "S551-S552",
    publisher = "Elsevier",
    issn = "0923-7534, 1569-8041",
    doi = "10.1016/j.annonc.2020.08.770"
}